Hematologic Neoplasms: Clinical Trials

67 trials for Hematologic Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

67 terminated. 67 Phase 1, 22 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 167Terminated 67
Phase 222Terminated 22

Follow Hematologic Neoplasms: new trials by email Literature Review of Hematologic Neoplasms trials Research Report on Hematologic Neoplasms

Trials (filtered) newest first · largest first

All 67 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
PF-08046032, Sasanlimab - Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma
Phase 1TerminatedPfizer62025-05-082026-05-08
A Phase I Study of BR108 in Hematological Malignancies
BR108 injection - Hematologic Malignancy
Phase 1TerminatedBioRay Pharmaceutical Co., Ltd.82023-03-182025-11-21
SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.
SG2501 - Hematological Malignancy, Lymphoma
Phase 1TerminatedHangzhou Sumgen Biotech Co., Ltd.22023-03-032025-03-18
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
Virus-specific Cytotoxic T-lymphocytes - Adenovirus Infection, BK Virus Infection
Phase 1TerminatedM.D. Anderson Cancer Center122023-01-062026-08-11
A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies
ATG-018 - Advanced Solid Tumors, Hematological Malignancies
Phase 1TerminatedAntengene Discovery Limited222022-07-082024-07-18
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
PRT1419, Azacitidine, Venetoclax - Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma
Phase 1TerminatedPrelude Therapeutics Incorporated212022-03-222024-01-31
Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study
Questionnaire Administration, Sotrovimab, Biospecimen Collection - COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm
Phase 1TerminatedFred Hutchinson Cancer Center202022-01-252025-02-13
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
Omacetaxine Mepesuccinate, Venetoclax - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Biphenotypic Leukemia
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center242021-12-172025-11-03
A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
EMB-06 - Relapsed or Refractory Multiple Myeloma
Phase 1 / Phase 2TerminatedShanghai EpimAb Biotherapeutics Co., Ltd.402021-05-202025-05-28
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
DS-1594b, Azacitidine, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center172021-03-252025-05-23
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
Bintrafusp Alfa, Pimasertib, Quality-of-Life Assessment - Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center82021-01-152026-03-18
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
TAS1553 - Acute Myeloid Leukemia, Myeloproliferative Neoplasm
Phase 1TerminatedAstex Pharmaceuticals, Inc.202020-12-212024-08-02
Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
Recombinant Interferon Alfa-2b, Rintatolimod - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Phase 1 / Phase 2TerminatedRoswell Park Cancer Institute42020-11-172026-01-13
Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies
ATG-017, ATG-017+Nivolumab - Solid Tumor, Hematological Malignancy
Phase 1TerminatedAntengene Therapeutics Limited362020-08-152024-07-23
A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers
ABBV-184 - Acute Myeloid Leukemia (AML), Non Small Cell Lung Cancer
Phase 1TerminatedAbbVie142020-05-052022-09-08
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8
Phase 1TerminatedOHSU Knight Cancer Institute22020-04-012024-03-04
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
CYNK-001 - Leukemia, Leukemia, Myeloid
Phase 1TerminatedCelularity Incorporated272020-03-122024-12-12
Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.
MB-102, Fludarabine, Cyclophosphamide - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase 1 / Phase 2TerminatedMustang Bio32020-02-172024-07-22
A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors
AZD0466 - Advanced Solid Tumors, Lymphoma
Phase 1TerminatedAstraZeneca92019-12-162023-08-02
Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy
IMM01 - Hematologic Malignancy
Phase 1TerminatedImmuneOnco Biopharmaceuticals (Shanghai) Inc.732019-11-192023-05-16

Showing 20 of 67. Sign in to see all of them.

Narrower conditions

Leukemia, Myeloid, Acute (20)  ·  Myelodysplastic Syndromes (14)  ·  Multiple Myeloma (13)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (11)  ·  Lymphoma, Non-Hodgkin (11)  ·  Primary Myelofibrosis (11)  ·  Hodgkin Disease (10)  ·  Lymphoma (10)  ·  Myeloproliferative Disorders (9)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (9)  ·  Leukemia (8)  ·  Leukemia, Myelomonocytic, Chronic (8)  ·  Polycythemia Vera (8)  ·  Recurrence (8)

Broader conditions

Hemic and Lymphatic Diseases (67)  ·  Neoplasms by Site (67)  ·  Hematologic Diseases (66)  ·  Neoplasms (60)  ·  Neoplasms by Histologic Type (36)  ·  Immune System Diseases (28)  ·  Immunoproliferative Disorders (27)  ·  Lymphoproliferative Disorders (27)  ·  Lymphatic Diseases (25)  ·  Pathologic Processes (24)  ·  Pathological Conditions, Signs and Symptoms (24)  ·  Bone Marrow Diseases (23)  ·  Disease Attributes (20)  ·  Leukemia (20)  ·  Leukemia, Myeloid (20)

Interventions

Azacitidine (5)  ·  fludarabine (5)  ·  Cytarabine (4)  ·  Nivolumab (4)  ·  fludarabine phosphate (4)  ·  venetoclax (4)  ·  Cyclophosphamide (3)  ·  Leucovorin (3)  ·  AP 1903 reagent (2)  ·  Alemtuzumab (2)  ·  Daunorubicin (2)  ·  Methotrexate (2)  ·  Panobinostat (2)  ·  Rituximab (2)  ·  Specimen Handling (2)

Sponsors

M.D. Anderson Cancer Center (8)  ·  Fred Hutchinson Cancer Center (3)  ·  Gilead Sciences (3)  ·  Incyte Corporation (3)  ·  Bellicum Pharmaceuticals (2)  ·  Exelixis (2)  ·  National Cancer Institute (NCI) (2)  ·  Pfizer (2)  ·  Roswell Park Cancer Institute (2)  ·  AbbVie (1)  ·  Acrotech Biopharma Inc. (1)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Antengene Discovery Limited (1)  ·  Antengene Therapeutics Limited (1)  ·  Astex Pharmaceuticals, Inc. (1)

Countries

United States (54)  ·  Italy (5)  ·  Canada (4)  ·  Spain (4)  ·  Australia (3)  ·  China (3)  ·  France (3)  ·  Japan (3)  ·  United Kingdom (3)  ·  Israel (2)  ·  Belarus (1)  ·  Belgium (1)  ·  Bulgaria (1)  ·  Czechia (1)  ·  Georgia (1)

Top investigators

Alpana Waghmare (1)  ·  Amit Mahipal, M.D. (1)  ·  Anupa Kudva, MD (1)  ·  Chris Storgard, MD (1)  ·  Courtney DiNardo, MD (1)  ·  David Maloney (1)  ·  David Stewart (1)  ·  Dolores Grosso, DNP, CRNP (1)

Results publications

PMID 23682558, PMID 28017967, PMID 29191916, PMID 29233821, PMID 30962222, PMID 31527168, PMID 33357452, PMID 33451977, PMID 35226739, PMID 36452492, PMID 36841672, PMID 36841758, PMID 36873868, PMID 36888930, PMID 38946484, PMID 39863139, PMID 40373381, PMID 40979071

NIH funding

2017 (3), 2016 (1), 2019 (1), P30CA016056 (1), P30CA016672 (1), P30CA072720 (1), P50CA100632 (1), R01CA114536 (1), U01CA062461 (1), U01CA062490 (1), U10CA031946 (1)